AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Asston Pharmaceuticals IPO Sees 26x Subscription on Final Day, GMP at 24%
ByAinvest
Friday, Jul 11, 2025 1:41 am ET1min read
Asston Pharmaceuticals' IPO has been subscribed 26.68 times, with bids for 38.04 million shares against the 1.6 million shares on offer. The SME offering has received bids from retail and non-institutional investors, with the qualified institutional buyers' portion subscribed 7.98 times. The unlisted shares are trading at ₹153, commanding a 24.39% premium compared to the upper end of the price band. The company plans to raise ₹27.56 crore through a fresh issue of 2.24 million equity shares.
Asston Pharmaceuticals' initial public offering (IPO) has received an overwhelming response from investors, with bids for 38.04 million shares against the 1.6 million shares on offer. The SME offering, which opened on Wednesday, July 9, has been subscribed 26.68 times, according to data from the BSE [3].The demand for Asston Pharmaceuticals' shares was driven primarily by retail and non-institutional investors (NIIs). The retail investors' portion was subscribed 33.10 times, while the NIIs' portion was subscribed 33.7 times. The qualified institutional buyers (QIBs) portion was subscribed 7.98 times [3].
The unlisted shares of Asston Pharmaceuticals are currently trading at ₹153 in the grey market, commanding a premium of ₹30 or 24.39% over the upper end of the price band of ₹115 to ₹123 [3].
Asston Pharmaceuticals plans to raise ₹27.56 crore through a fresh issue of 2.24 million equity shares. The funds will be used for acquiring machinery in the manufacturing unit, meeting working capital requirements, repaying debt, and general corporate purposes [1].
The IPO, which opened for subscription on Wednesday, July 9, will close today, July 11, 2025. The basis of allotment is expected to be finalized on Monday, July 14, 2025, with shares scheduled to be listed on the BSE SME platform tentatively on Wednesday, July 16, 2025 [1, 2, 3].
References:
[1] https://m.economictimes.com/markets/ipos/fpos/asston-pharmaceuticals-ipo-opens-for-subscription-with-decent-gmp-check-details/articleshow/122331266.cms
[2] https://www.business-standard.com/markets/news/retail-investors-drive-demand-for-asston-pharmaceuticals-ipo-gmp-at-24-125071000511_1.html
[3] https://www.business-standard.com/markets/news/asston-pharmaceuticals-ipo-closes-today-subscription-rises-26x-gmp-at-24-125071100364_1.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet